Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): Candidate biomarker for immunotherapy in Alzheimer's disease and cerebral amyloid angiopathy

Jacopo C. Di Francesco, Martina Longoni, Fabrizio Piazza

Research output: Contribution to journalArticle

Abstract

Amyloid-related imaging abnormalities (ARIA) represent the major severe side effect of amyloid-beta (Aβ) immunotherapy for Alzheimer's disease (AD). Early biomarkers of ARIA represent an important challenge to ensure safe and beneficial effects of immunotherapies, given that different promising clinical trials in prodromal and subjects at risk for AD are underway. The recent demonstration that cerebrospinal fluid (CSF) anti-Aβ autoantibodies play a key role in the development of the ARIA-like events characterizing cerebral amyloid angiopathy-related inflammation generated great interest in the field of immunotherapy. Herein, we critically review the growing body of evidence supporting the monitoring of CSF anti-Aβ autoantibody as a promising candidate biomarker for ARIA in clinical trials.

Original languageEnglish
Article number207
JournalFrontiers in Neurology
Volume6
Issue numberSEP
DOIs
Publication statusPublished - 2015

Keywords

  • Alzheimer's disease
  • Amyloid-related imaging abnormalities
  • Anti-amyloid antibody clinical trials
  • Aβ disease modifying therapies
  • Cerebral amyloid angiopathy related inflammation
  • Cerebrospinal fluid biomarker
  • ICAβ International Network
  • Immunotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): Candidate biomarker for immunotherapy in Alzheimer's disease and cerebral amyloid angiopathy'. Together they form a unique fingerprint.

  • Cite this